Methodological Reports:

Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing

Renee C. Tschumper, Yan W. Asmann, Asif Hossain, Paul M. Huddleston, Xiaosheng Wu, Angela Dispenzieri, Bruce W. Eckloff and Diane F. Jelinek _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2012; 3:502-513. https://doi.org/10.18632/oncotarget.469

Metrics: PDF 3030 views  |   HTML 3690 views  |   ?  


Renee C. Tschumper1, Yan W. Asmann2, Asif Hossain2, Paul M. Huddleston3, Xiaosheng Wu1, Angela Dispenzieri4, Bruce W. Eckloff5 and Diane F. Jelinek1

1 Department of Immunology, Mayo Clinic, Rochester, MN, USA

2 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

3 Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA

4 Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

5 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA

Received: March 24, 2012; Accepted: April 18, 2012; Published: April 20, 2012;

Keywords: IGHV, multiple myeloma, heterogeneity, massively parallel sequencing


Diane F. Jelinek, email:


Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells (PCs) in the bone marrow (BM). MM is viewed as a clonal disorder due to lack of verified intraclonal sequence diversity in the immunoglobulin heavy chain variable region gene (IGHV). However, this conclusion is based on analysis of a very limited number of IGHV subclones and the methodology employed did not permit simultaneous analysis of the IGHV repertoire of non-malignant PCs in the same samples. Here we generated genomic DNA and cDNA libraries from purified MM BMPCs and performed massively parallel pyrosequencing to determine the frequency of cells expressing identical IGHV sequences. This method provided an unprecedented opportunity to interrogate the presence of clonally related MM cells and evaluate the IGHV repertoire of non-MM PCs. Within the MM sample, 37 IGHV genes were expressed, with 98.9% of all immunoglobulin sequences using the same IGHV gene as the MM clone and 83.0% exhibiting exact nucleotide sequence identity in the IGHV and heavy chain complementarity determining region 3 (HCDR3). Of interest, we observed in both genomic DNA and cDNA libraries 48 sets of identical sequences with single point mutations in the MM clonal IGHV or HCDR3 regions. These nucleotide changes were suggestive of putative subclones and therefore were subjected to detailed analysis to interpret: 1) their legitimacy as true subclones; and 2) their significance in the context of MM. Finally, we report for the first time the IGHV repertoire of normal human BMPCs and our data demonstrate the extent of IGHV repertoire diversity as well as the frequency of clonally-related normal BMPCs. This study demonstrates the power and potential weaknesses of in-depth sequencing as a tool to thoroughly investigate the phylogeny of malignant PCs in MM and the IGHV repertoire of normal BMPCs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 469